Brief: Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted To Setmelanotide For Treatment Of Hypothalamic Obesity In Japan
19/03/2025 20:54
Rhythm Pharmaceuticals Inc RYTM.O: RHYTHM PHARMACEUTICALS ANNOUNCES ORPHAN DRUG DESIGNATION GRANTED TO SETMELANOTIDE FOR TREATMENT OF HYPOTHALAMIC OBESITY IN JAPAN RHYTHM PHARMACEUTICALS:SETMELANOTIDE IN GLOBAL PHASE 3 TRIAL FOR ACQUIRED HYPOTHALAMIC OBESITY, WITH TOPLINE DATA ON TRACK TO BE DISCLOSED IN Q2 2025 Source text: ID:nGNXbmcbyQ Further company coverage: RYTM.O
Recent news on Rhythm Pharmaceuticals
See all newsBrief: Rhythm Pharmaceuticals Announces Appointment Of Manher (Aj) Joshi As Chief Medical Officer
Rhythm's drug shows promise for brain tumor-related weight condition in small study (updated)
Rhythm Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition
Rhythm Pharmaceuticals Q2 net loss narrows on US launch demand